Altered levels of urokinase on monocytes and in serum of children with AIDS; effects on lymphocyte activation and surface marker expression.
Urokinase (UK) type plasminogen activator is a serine protease produced by activated human monocytes. Despite the well-documented roles played by UK in cell-mediated immunity in healthy humans, the roles played by UK in the derangements of cell-mediated immune responses observed in HIV disease remain largely undefined. In these studies the numbers of peripheral blood lymphocytes and monocytes bearing surface UK (UK+) as well as serum levels of UK (flow microfluorimetry and ELISA, respectively) were determined in children with AIDS and in healthy HIV-negative children. The effects of exogenous UK on lymphocyte activation (cell cycle analysis using living cells) and surface marker (CD3, CD4, CD8, and CD19) expression (flow microfluorimetry using fixed cells) were also studied. Data are expressed as percent total cells. Numbers of UK+ lymphocytes in children with AIDS were similar to those observed in healthy children. In contrast, numbers of UK+ peripheral blood monocytes were dramatically decreased (> 70%) in the children with AIDS. However, serum levels of UK were increased (nearly threefold) in these children. When lymphocytes from these children were cultured with soluble UK, numbers of cells in S phase of cell cycle appeared suppressed. Incubation of fixed lymphocytes from either a child with AIDS or from a healthy child with exogenous UK appeared to increase numbers of cells expressing CD3. Incubation with UK had no effect on expression of any other surface marker (CD4, CD8, or CD19) using cells from the child with AIDS. In contrast, incubation with UK appeared to decrease (fivefold) numbers of cells expressing CD19 and increase numbers of cells expressing CD4 and CD8 only when fixed lymphocytes from a healthy HIV-negative child were used. The results suggest important roles for UK in regulation of lymphocyte surface markers in general and in CD3- and CD19-dependent lymphocyte activation pathways specifically. Furthermore, these studies add to a widening body of evidence implicating UK dysregulation in the pathogenesis of HIV disease and may point to pharmacological opportunities involving UK to delay or prevent progression of HIV infection into full-blown AIDS.
Murali
R
R
Department of Pathology, State University of New York Health Science Center at Brooklyn, NY 11203, USA.
Wolfe
J H
JH
Erber
R
R
Chice
S M
SM
Murali
M R
MR
Durkin
H G
HG
Zach
P
P
Auci
D L
DL
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology*; D018941:Antigens, CD19 / Q000032:analysis / Q000276:immunology; D015415:Biomarkers; D017252:CD3 Complex / Q000032:analysis / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000737:chemistry / Q000276:immunology / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000737:chemistry / Q000276:immunology / Q000821:virology; D002453:Cell Cycle / Q000276:immunology; D002648:Child; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006679:HIV Seropositivity; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D008297:Male; D009000:Monocytes / Q000737:chemistry / Q000201:enzymology / Q000821:virology*; D010960:Plasminogen Activators / Q000032:analysis / Q000097:blood* / Q000276:immunology; D012995:Solubility; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis / Q000097:blood* / Q000276:immunology
D018941:Antigens, CD19; D015415:Biomarkers; D017252:CD3 Complex; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator